135 related articles for article (PubMed ID: 29566837)
1. Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients.
Zhong Y; Valderrama A; Yao J; Donga P; Bilir P; Neumann PJ
Value Health; 2018 Mar; 21(3):304-309. PubMed ID: 29566837
[TBL] [Abstract][Full Text] [Related]
2. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
[TBL] [Abstract][Full Text] [Related]
4. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer.
Delea TE; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Thorac Oncol; 2006 Jul; 1(6):571-6. PubMed ID: 17409919
[TBL] [Abstract][Full Text] [Related]
5. The cost of treating skeletal-related events in patients with prostate cancer.
Lage MJ; Barber BL; Harrison DJ; Jun S
Am J Manag Care; 2008 May; 14(5):317-22. PubMed ID: 18471035
[TBL] [Abstract][Full Text] [Related]
6. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Bhowmik D; Hines DM; Intorcia M; Wade RL
J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
[TBL] [Abstract][Full Text] [Related]
7. The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.
McDougall JA; Bansal A; Goulart BH; McCune JS; Karnopp A; Fedorenko C; Greenlee S; Valderrama A; Sullivan SD; Ramsey SD
Oncologist; 2016 Mar; 21(3):320-6. PubMed ID: 26865591
[TBL] [Abstract][Full Text] [Related]
8. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.
Hagiwara M; Delea TE; Saville MW; Chung K
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):23-7. PubMed ID: 23146970
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
[TBL] [Abstract][Full Text] [Related]
10. Costs of prostate cancer, metastatic to the bone, in the Netherlands.
Groot MT; Boeken Kruger CG; Pelger RC; Uyl-de Groot CA
Eur Urol; 2003 Mar; 43(3):226-32. PubMed ID: 12600424
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events.
Ailawadhi S; Medhekar R; Princic N; Fowler R; Tran O; Bhowmik D; Panjabi S
J Oncol Pharm Pract; 2020 Jul; 26(5):1070-1079. PubMed ID: 31631810
[TBL] [Abstract][Full Text] [Related]
12. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.
Barlev A; Song X; Ivanov B; Setty V; Chung K
J Manag Care Pharm; 2010; 16(9):693-702. PubMed ID: 21067255
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer.
Yong C; Onukwugha E; Mullins CD
Curr Opin Oncol; 2014 May; 26(3):274-83. PubMed ID: 24626126
[TBL] [Abstract][Full Text] [Related]
14. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
15. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
Bhowmik D; Song X; Intorcia M; Gray S; Shi N
Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
[TBL] [Abstract][Full Text] [Related]
16. Canadian health care institution resource utilization resulting from skeletal-related events.
Habib MJ; Merali T; Mills A; Uon V
Hosp Pract (1995); 2014 Feb; 42(1):15-22. PubMed ID: 24566592
[TBL] [Abstract][Full Text] [Related]
17. Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events.
Hardtstock F; Kocaata Z; Wilke T; Dittmar A; Ghiani M; Belozeroff V; Harrison DJ; Maywald U; Tesch H
Eur J Health Econ; 2021 Mar; 22(2):243-254. PubMed ID: 33459901
[TBL] [Abstract][Full Text] [Related]
18. Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands.
Ter Heine R; Frederix GW; Geenen JW; Hövels AM; van Vulpen M; Kooistra A; De Klerk JM; Bloemendal HJ
J Comp Eff Res; 2017 Oct; 6(7):575-581. PubMed ID: 29091013
[TBL] [Abstract][Full Text] [Related]
19. Short-term disability in solid tumor patients with bone metastases and skeletal-related events.
Qian Y; Song X; Zhang K; Balakumaran A; Arellano J
J Med Econ; 2015 Mar; 18(3):210-8. PubMed ID: 25426582
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M
Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
